The FDA approved the Novartis AG's Rydapt on April 28. The drug is targeted toward AML patients and the FDA lists it for $22,500 for an average 42-day treatment.
Medicine May 1, 2017
Acute myeloid leukemia (AML) is actually an umbrella term for 11 distinct subtypes of the illness, new research has revealed. This finding could revolutionize treatment and diagnosis.
Public Health June 11, 2016
Novartis' Midostaurin showed promising results in the survival rate of patients diagnosed with AML. Also known as PKC412, the drug will be set for regulatory submissions by 2016.
Life December 7, 2015
Now there’s another thing to love avocados for. Researchers have discovered that a compound derived from the fruit has the potential to treat acute myeloid leukemia.
Life June 16, 2015
American health care company Baxter International has purchased two cancer drugs from Sigma-Tau Finanziaria SpA valued at $900 million. Both drugs are designed to treat patients with a rare form of blood cancer called acute lymphoblastic leukemia.
Deals May 13, 2015